Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (286)	5/28/1998 11:15:00 AM
From: Rob-Chemist	Read Replies (1) \| Respond to of 328

I would strongly disagree with your characterization of this as bad news, and would instead consider it very good news. I would not be surprised if a large number of other drug companies also license the SELEX technology for target validation, thereby providing NXTR with a significant influx of cash. I think that it is significant that they did not sell the rights to using the SELEX either for the development of new drugs or diagnostics. Finally, this may be the start of a larger collaboration between Glaxo-Wellcome and NXTR. A few years ago, Burrows-Wellcome (prior to the merger with Glaxo) was very interested in the diagnostic aspects of SELEX. NXTR, however, decided to collaborate with other companies at the time.